Your session is about to expire
← Back to Search
Palbociclib for Cancer
Study Summary
This trial is testing the effects ofpalbociclib in patients with cancer that has genetic changes called CCND1, 2, or 3 amplification. Palbociclib may stop the growth of cancer cells by blocking proteins called CDK4 and CDK6.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 55 Patients • NCT03007979Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have heart issues related to the left ventricle.I do not have breast cancer, mantle cell lymphoma, or myeloma.My recent ECG showed no significant heart issues.I am not taking any strong medications or eating foods that affect certain liver enzymes.I am not allergic to palbociclib or similar drugs.I have not been treated with CDK4/6 inhibitors like palbociclib.My cancer has a specific genetic change related to CCND1, 2, or 3.
- Group 1: Treatment (palbociclib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For which ailments is Palbociclib administered as a treatment?
"Palbociclib has been approved for treating breast cancer but is also used to address other illnesses like malignant neoplasms, postmenopausal conditions, and advanced directives."
Has Palbociclib been sanctioned by the Food and Drug Administration?
"Palbociclib's safety has been demonstrated to a certain degree in Phase 2 trials, meriting it an assessment of '2' on our 1-3 scale. However, efficacy data is still lacking."
Are there any current opportunities for individuals to participate in this trial?
"This medication trial is not presently enrolling, as the posting on clinicaltrials.gov indicates it was last modified on September 14th 2022. Nonetheless, 4116 other studies are currently recruiting patients for their trials."
Are there any other experiments conducted with Palbociclib that have been documented?
"Currently, 133 study groups are examining palbociclib. Of those trials, 16 have reached the 3rd phase of their research. Several locations in Burgas, New jersey are running studies for this medication; however, there are 6577 sites worldwide with active clinical trials related to palbociclib."
How many participants comprise this research endeavor?
"Unfortunately, this research has stopped taking on new candidates. Initially posted in May of 2016, the trial was last revised in September of 2022. However, if you are still looking to get involved with clinical trials regarding lymphoma there are 3983 studies currently open and 133 related to Palbociclib that need volunteers."
Share this study with friends
Copy Link
Messenger